STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

AMRX Schedule 13G filing by UBS

UBS reported beneficial ownership of 21.5M shares, representing 6.94% of AMNEAL PHARMACEUTICALS INC in this filing.

FiledOct 30, 2024
Ownership dateSep 30, 2024
Reported shares21.5M
Reported ownership6.94%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 0
Shared voting power 14.7K
Sole dispositive power 0
Shared dispositive power 21.5M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$8.57as of Oct 30, 2024
Latest tracked price$18.69as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
UBS
CIK
CIK0001610520
Accession
0001610520-24-000160
Form
Schedule 13G
Open SEC filing View AMRX ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →